Search
Search Results
-
Is switching intravesical chemotherapeutic agents beneficial in short-term recurrent high-risk non-muscle-invasive bladder tumors? A 5-year retrospective study
ObjectiveTo explore if switching intravesical chemotherapeutic agents is beneficial in short-term recurrences of high-risk non-muscle-invasive...
-
Inhibition of FEN1 promotes DNA damage and enhances chemotherapeutic response in prostate cancer cells
Prostate cancer (PCa) refers to epithelial malignancies occurring in prostate and is the most commonly diagnosed cancer among men. Flap...
-
Role of natural P-gp inhibitor in the effective delivery for chemotherapeutic agents
Multi-drug resistance has shown to be one of the leading threats faced currently in many chemotherapeutic agents. Permeability glycoprotein (P-gp) is...
-
Impact of Chemotherapeutic Agents on PD-L1, CTLA-4, and VISTA Gene Expression in Cervical Cancer Cell Lines: An In Vitro Study
PurposeThe study aims to understand how docetaxel and doxorubicin, two commonly used chemotherapeutic drugs, influence the expression of PD-L1,...
-
Establishing the applicability of cancer vaccines in combination with chemotherapeutic entities: current aspect and achievable prospects
Cancer immunotherapy is one of the recently developed cancer treatment modalities. When compared with conventional anticancer drug regimens,...
-
USP35 promotes cell proliferation and chemotherapeutic resistance through stabilizing FUCA1 in colorectal cancer
Ubiquitin-specific-processing proteases 35 (USP35) is an under-characterized deubiquitinase and its role in colorectal cancer (CRC) remains unclear....
-
TNFα-induced IDH1 hyperacetylation reprograms redox homeostasis and promotes the chemotherapeutic sensitivity
The heterogeneity and drug resistance of colorectal cancer (CRC) often lead to treatment failure. Isocitrate dehydrogenase 1 (IDH1), a rate-limiting...
-
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas
PurposeThoracic sarcomas are rare malignancies, with limited data for unresectable/advanced scenarios. Our goal is to provide insights of a...
-
Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent
Fisetin, a natural flavonoid, possesses numerous biological activities that have been extensively studied in various diseases. When it comes to...
-
D,L-Methadone enhances the cytotoxic activity of standard chemotherapeutic agents on pediatric rhabdomyosarcoma
PurposeIn advanced tumor stages, pediatric rhabdomyosarcoma (RMS) shows an intrinsic resistance to standard chemotherapy, which is associated with a...
-
A comparative study between two methods of delivery of chemotherapeutic agent in patients with bone and soft tissue sarcoma of lower extremity
BackgroundWe aimed to compare the effects of peripherally inserted central catheters (PICC) and implantable venous access devices (TIVADs) in terms...
-
Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator
In develo** new cancer medications, attention has been focused on novel epigenetic medicines called histone deacetylase (HDAC) inhibitors. Our...
-
Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2( +) breast cancer, multiple myeloma, and non-small-cell lung cancer
HypothesisBiological response modifiers (immunotherapy) in combination to chemotherapy are superior to that of chemotherapy in treatment of breast...
-
Recent advances and applications of peptide–agent conjugates for targeting tumor cells
BackgroundCancer, being a complex disease, presents a major challenge for the scientific and medical communities. Peptide therapeutics have played a...
-
Nuclear Imaging for the Assessment of Cardiotoxicity from Chemotherapeutic Agents in Oncologic Disease
Purpose of ReviewIn this review, we summarize the major known cardiac toxicities of common chemotherapeutic agents and the role of nuclear cardiac...
-
Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells
PurposeDrug efflux transporter associated multi-drug resistance (MDR) is a potential limitation in the use of taxane chemotherapies for the treatment...
-
The Use of Single-Agent Versus Multiple-Agent Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Rectal Cancer
PurposeThe use of concurrent chemoradiotherapy is frequently recommended in the treatment of locally advanced rectal cancer; however, the ideal...
-
Cardiotoxicities of Non-Chemotherapeutic Metastatic Breast Cancer Treatments
Purpose of ReviewAlthough mortality rates have declined significantly in recent years, breast cancer remains the second most common cause of cancer...
-
MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer
Despite paclitaxel’s wide use in cancer treatment, patient response rate is still low and drug resistance is a major clinical obstacle. Through a...
-
Flavonoid Myricetin as Potent Anticancer Agent: A Possibility towards Development of Potential Anticancer Nutraceuticals
Good nutrition plays a crucial role in maintaining a balanced lifestyle. The beneficial effects of nutrition have been found to counteract...